Navigate cell and gene therapy complexity with confidence

Address access, cost, reimbursement, and operational challenges through integrated cross-functional support.

Advanced therapies create opportunity and operational complexity simultaneously

We help organizations navigate procurement, reimbursement, and clinical challenges across access, affordability, and operations before demand outpaces readiness.

At a glance

The scale and growth of the advanced-therapy market opportunity

Approved therapies, projected spend, and pipeline depth define the advanced-therapy market opportunity.

33+

Active FDA-approved therapies

Source

$47B

Cell and Gene Therapy market to rise to $47B by 2035, driven by a CAGR of 18.1% over the forecast period

Source

238

Therapies in the pipeline

Source

Access and capacity

Plan for treatment-center and capacity constraints

Limited treatment centers and constrained capacity create implementation challenges. We help leaders understand how access realities affect readiness and service delivery planning, keeping expansion grounded in operational reality.

Affordability and reimbursement

Prepare for the financial complexity around advanced therapies

Advanced therapies create significant cost exposure and reimbursement complexity, including single-case agreements and patient-assistance planning. We help organizations address these challenges before therapies reach the bedside.

Operational readiness

Build the policies and processes these therapies require

Organizations must build handling policies, operational frameworks, and governance structures for this evolving category. We help teams navigate clinical and operational demands, creating readiness for market expansion.

Resource center